Vitaspring Biomedical CO LTD 10-Q quarterly reports

VitaSpring Biomedical reports a net loss of $75,844 for Q1 2026, with substantial doubt cast on its ability to continue as a going concern due to a significant working capital deficit and minimal cash reserves.

VitaSpring Biomedical's Q3 2025 report highlights significant financial challenges, including a substantial working capital deficit and a material weakness in internal controls, raising substantial doubt about its ability to continue as a going concern.

VitaSpring Biomedical's Q2 2026 report highlights significant financial challenges, including a severe working capital deficit and minimal cash, raising substantial doubt about its ability to continue as a going concern.

VitaSpring Biomedical reported zero revenue for the first quarter of fiscal year 2025, with a net loss of $80,541 and a significant increase in working capital deficiency.

VitaSpring Biomedical reports no revenue for Q3 2025, with a widening working capital deficit and ongoing concerns about its ability to continue as a going concern.

VitaSpring Biomedical Co., Ltd. filed its Form 10-Q for the quarter ended July 31, 2024, reporting no revenue and a net loss, while continuing to rely on related-party financing.

VitaSpring Biomedical Co., Ltd. reported a significant increase in net loss and zero revenue for the nine months ended October 31, 2023, raising substantial doubt about its ability to continue as a going concern.

VitaSpring Biomedical Co., Ltd. reported a significant net loss and no revenue for the quarter ended July 31, 2023, as it focuses on product strategy restructuring and seeks additional capital.

VitaSpring Biomedical Co., Ltd. reported a significant net loss and zero revenue for the quarter ended April 30, 2023, raising substantial doubt about its ability to continue as a going concern.